Table 1 Characteristics of allo-HSCT patients with PT and GGF
Characteristics | PTa (N = 17) | GGFa (N = 34) | P-value** |
|---|---|---|---|
BM evaluated time (post-HSCT days) | 64 (58–175) | 63 (58–178) | 0.67 |
Blood cell count | |||
Median WBC (×109/L) (range) | 3.20 (1.37–6.57) | 4.29 (1.79–6.50) | 0.08 |
Median ANC (×109/L) (range) | 2.57 (0.91–3.80) | 3.00 (0.98-5.20) | 0.31 |
Median Hb (g/L) (range) | 83 (73–126) | 108 (80–153) | <0.0001 |
Median PLT (×109/L) (range) | 22 (13–38) | 130 (82–239) | <0.0001 |
Age at HSCT (years, median, range) | 35 (18–60) | 35 (18–64) | 0.90 |
Gender (male/female) | 9/8 | 20/14 | 0.69 |
Underlying disease | 1.00 | ||
AML | 9 | 18 | |
ALL | 5 | 10 | |
MDS | 3 | 6 | |
Status at HSCT | 0.74 | ||
Standard-risk | 15 | 31 | |
High-risk | 2 | 3 | |
Source of stem cell | 1.00 | ||
BM and PB | 17 | 34 | |
Transplanted total nucleated cell dose (×108/kg, median, range) | 8.40 (7.05–9.84) | 8.88 (3.98–9.98) | 0.56 |
Transplanted CD34+ cell dose (×106/kg, median, range) | 2.05 (1.06–5.89) | 2.11 (1.02–5.85) | 0.89 |
Donor match | 1.00 | ||
HLA-identical sibling donor | 0 | 0 | |
HLA-partially matched related donor | 17 | 34 | |
Sex mismatch | 0.94 | ||
Female to male | 4 | 6 | |
Female to female | 1 | 3 | |
Male to female | 7 | 14 | |
Male to male | 5 | 11 | |
ABO mismatch | 0.27 | ||
No | 13 | 18 | |
Minor | 2 | 8 | |
Major | 2 | 8 | |
Pre-HSCT cycles of chemotherapy | 3 (0–6) | 3 (0–7) | 0.49 |
Conditioning | 1.00 | ||
BU/CY | 0 | 0 | |
BU/CY + ATG | 17 | 34 | |
History of CMV reactivation | 11 | 20 | 0.69 |
Onset of CMV reactivation (days, median, range) | 28 (8–72) | 24 (7–56) | 0.21 |
CMV reactivation treated with ganciclovir | 10 | 15 | 0.32 |
History of GvHD | 7 | 15 | 0.84 |
Onset of aGvHD (days, median, range) | 17 (7–60) | 14 (5–62) | 0.57 |
